Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) are a group of blood cancers.
• MPNs lacking classical driver mutations are termed triple negative MPNs (TN-MPNs).
• The pathogenesis of TN-MPNs remains poorly understood.

Purpose of the Study:

• To review the clinical features and prognosis of triple negative primary myelofibrosis (TN-PMF) and triple negative essential thrombocythemia (TN-ET).
• To discuss diagnostic challenges, including identifying non-canonical driver mutations in TN-MPNs.
• To explore potential molecular drivers and therapeutic strategies for TN-MPNs.

Main Methods:

• Literature review of clinical studies and molecular analyses.
• Summary of diagnostic criteria and prognostic factors for TN-MPNs.
• Discussion of current and novel therapeutic targets.

Main Results:

• TN-PMF has a poor prognosis, while TN-ET is more favorable than JAK2-mutated ET.
• Diagnostic challenges include identifying rare or non-canonical mutations.
• Understanding additional molecular drivers is crucial for elucidating pathogenesis.

Conclusions:

• TN-MPNs represent a distinct subgroup requiring further investigation.
• Accurate diagnosis and identification of molecular drivers are essential.
• Novel therapeutic approaches are needed, especially for TN-PMF.